ClinicalTrials.gg
CompletedNCT03330288Updated Oct 14, 2021Results posted

Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment

An observational study in Osteoarthritis, sponsored by Bayer. Completed at 2 sites in Russian Federation. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-14.

Sponsored by Bayer · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,102
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Osteoarthritis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Russian Federation.

Started
2017
the only one that year
Observational
3 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
1 of 20
Bayer

Among the 20 studies in Osteoarthritis with a site in Russian Federation, this one is the only one that started in 2017, is one of 3 observational ones, and was the 11th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 20 studies in Osteoarthritis with a site in Russian Federation is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Osteoarthritis with a site in Russian Federation as a file.
02

Study summary

The main purpose of this study is to evaluate how a long-term treatment with Theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient satisfaction with treatment.

Read the detailed description

Other information that is planned for evaluation in this study includes consumption of Theraflex, intake of analgesics for joint pain relief and description of basic patient characteristics such as age, weight and body mass index and others.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient who will be made aware about the study either by the treating physician OR by a pharmacist where a patient is purchasing Theraflex

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 45 to 75 years with Hip or Knee OA stage I to III
  • Patient started current treatment with Theraflex not more than 2 weeks prior to inclusion into the study
  • Personally signed and dated

Exclusion criteria

Exclusion Criteria:

  • Patients participating in an program with interventions outside of routine clinical practice
  • Patients with Hip or Knee OA stage 0 or stage IV
  • Patients who have both Hip and Knee OA and OA of any other location
  • for use of Theraflex in accordance with approved label(known , severe chronic renal failure)
  • Females who are pregnant or breastfeeding
  • Patients who completed a treatment with Theraflex or another combination of Gl+ Ch less than 5 months before start of the current treatment
  • Patients who completed intra-articular treatment in the last 3 months to exclusion criteria
  • Patients who completed hyaluronic injections of the lower limbs in the last 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,102 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with Stage I-III Knee osteoarthritis (KOA)

    Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment

    Drug: Theraflex, BAY 874017

  • Participants with Stage I-III Hip osteoarthritis (HOA)

    Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment

    Drug: Theraflex, BAY 874017

Interventions

  • DrugTheraflex, BAY 874017

    The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day

06

What researchers measure

Primary outcomes

  1. Changes in the Pain Intensity Subscale

    KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.

    Time frame: From enrollment up to 64 weeks

  2. Changes in Other Symptoms Subscale

    KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.

    Time frame: From enrollment up to 64 weeks

  3. Change in Functional Activity of the Joint Subscale

    KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.

    Time frame: From enrollment up to 64 weeks

  4. Change in Life Quality Subscale

    KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.

    Time frame: From enrollment up to 64 weeks

Secondary outcomes

  1. Number of Participant Compliance With Drug Utilization of Theraflex

    Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.

    Time frame: From enrollment up to 64 weeks

  2. Change in Patient Satisfaction Assessment

    Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied

    Time frame: From enrollment up to 64 weeks

  3. Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)

    Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.

    Time frame: From enrollment up to 64 weeks

  4. Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex

    Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.

    Time frame: From enrollment up to 64 weeks

07

Results

Posted Oct 14, 2021

Participant flow

Study was conducted at 51 centers in Russian Federation, between 20-Nov-2017 (first participant first visit) and 13-Jul-2020 (Database clean). The Primary Completion date is 18-Mar-2020 (last participant last visit)

Participant flow — Overall Study
MilestoneParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
Started824278
Completed794270
Not completed308
Withdrew: Other reason11
Withdrew: Switching to a different disease-modifying delayed-release drug sysadoa10
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up267

Outcome measures

PrimaryChanges in the Pain Intensity Subscale

KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.

Time frame:
From enrollment up to 64 weeks
Reported as:
Mean · Scores on a scale
Changes in the Pain Intensity Subscale
Scores on a scaleParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
From Visit 1(enrollment) to Visit 2 (Week 16-24)18.07 ± 16.90015.59 ± 16.686
From Visit 1(enrollment) toVisit 3 (Week 36-44)20.92 ± 17.94620.06 ± 17.686
From Visit 1(enrollment) toVisit 4 (Week 56-64)22.87 ± 18.81522.81 ± 19.550
PrimaryChanges in Other Symptoms Subscale

KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.

Time frame:
From enrollment up to 64 weeks
Reported as:
Mean · Scores on a scale
Changes in Other Symptoms Subscale
Scores on a scaleParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
From Visit 1(enrollment) to Visit 2 (Week 16-24)15.48 ± 17.46512.65 ± 16.937
From Visit 1(enrollment) toVisit 3 (Week 36-44)18.87 ± 18.68517.10 ± 17.811
From Visit 1(enrollment) toVisit 4 (Week 56-64)20.78 ± 19.33019.93 ± 20.318
PrimaryChange in Functional Activity of the Joint Subscale

KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.

Time frame:
From enrollment up to 64 weeks
Reported as:
Mean · Scores on a scale
Change in Functional Activity of the Joint Subscale
Scores on a scaleParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
From Visit 1(enrollment) to Visit 2 (Week 16-24)10.98 ± 11.83113.26 ± 15.729
From Visit 1(enrollment) to Visit 3 (Week 36-44)14.26 ± 13.70816.41 ± 16.584
From Visit 1(enrollment) to Visit 4 (Week 56-64)16.60 ± 14.50318.77 ± 18.041
PrimaryChange in Life Quality Subscale

KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.

Time frame:
From enrollment up to 64 weeks
Reported as:
Mean · Scores on a scale
Change in Life Quality Subscale
Scores on a scaleParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
From Visit 1(enrollment) to Visit 2 (Week 16-24)16.29 ± 17.88814.25 ± 18.068
From Visit 1(enrollment) to Visit 3 (Week 36-44)20.79 ± 19.62518.82 ± 18.915
From Visit 1(enrollment) to Visit 4 (Week 56-64)24.87 ± 21.05522.71 ± 21.444
SecondaryNumber of Participant Compliance With Drug Utilization of Theraflex

Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.

Time frame:
From enrollment up to 64 weeks
Reported as:
Number · Participant
Number of Participant Compliance With Drug Utilization of Theraflex
ParticipantParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
Participant followed the recommendations753253
Participant not followed the recommendations5921
No data available124
SecondaryChange in Patient Satisfaction Assessment

Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied

Time frame:
From enrollment up to 64 weeks
Reported as:
Mean · Scores on a scale
Change in Patient Satisfaction Assessment
Scores on a scaleParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
From Visit 1(enrollment) to Visit 2 (Week 16-24)0.8 ± 0.840.8 ± 0.87
From Visit 1(enrollment) to Visit 3 (Week 36-44)0.8 ± 0.890.9 ± 0.81
From Visit 1(enrollment) to Visit 4 (Week 56-64)0.9 ± 0.940.9 ± 0.94
SecondaryNumber of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)

Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.

Time frame:
From enrollment up to 64 weeks
Reported as:
Number · Participant
Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)
ParticipantParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
Symptomatic therapy with analgesics for the target joint OA274103
Other drug treatment for pain syndrome of the target joint OA8425
Other therapy for the target joint OA364
SecondaryNumber of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex

Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.

Time frame:
From enrollment up to 64 weeks
Reported as:
Number · Participant
Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex
ParticipantParticipants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)
Symptomatic therapy with analgesics for the target joint OA205
Other drug treatment for pain syndrome of the target joint OA116
Other therapy for the target joint OA90

Adverse events

Collected over After initial administration of Theraflex up to 64 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Stage I-III Hip Osteoarthritis (HOA)0/278 (0%)6/278 (2.2%)28/278 (10.1%)
Participants With Stage I-III Knee Osteoarthritis (KOA)1/824 (0.1%)8/824 (1%)55/824 (6.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventParticipants With Stage I-III Hip Osteoarthritis (HOA)Participants With Stage I-III Knee Osteoarthritis (KOA)
Angina pectorisCardiac disorders1/2780/824
Atrial fibrillationCardiac disorders1/2782/824
Cardiac failure chronicCardiac disorders1/2780/824
Ischaemic cardiomyopathyCardiac disorders1/2780/824
Myocardial ischaemiaCardiac disorders1/2780/824
TachycardiaCardiac disorders1/2780/824
CholelithiasisHepatobiliary disorders1/2780/824
Foot fractureInjury, poisoning and procedural complications1/2780/824
MyositisMusculoskeletal and connective tissue disorders1/2780/824
Radicular painNervous system disorders1/2780/824
Most frequent other events
Most frequent other events
EventParticipants With Stage I-III Hip Osteoarthritis (HOA)Participants With Stage I-III Knee Osteoarthritis (KOA)
Respiratory tract infectionInfections and infestations7/27818/824
Abdominal pain upperGastrointestinal disorders2/27812/824
Abdominal discomfortGastrointestinal disorders4/2781/824
Back painMusculoskeletal and connective tissue disorders4/2782/824
OsteoarthritisMusculoskeletal and connective tissue disorders4/2789/824
HypertensionVascular disorders4/2782/824
HeadacheNervous system disorders3/27811/824
ArthralgiaMusculoskeletal and connective tissue disorders3/2785/824
OsteochondrosisMusculoskeletal and connective tissue disorders3/2784/824

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Mean60.4 ± 6.960.3 ± 7.2160.4 ± 6.97
Sex: Female, Male
Sex: Female, Male(Participants)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Female728240968
Male9638134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American101
White8202781098
More than one race000
Unknown or Not Reported000
Pain intensity subscale
Pain intensity subscale(Scores on a scale)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Mean61.48 ± 16.43460.97 ± 17.321NA ± NA
Other symptom subscale
Other symptom subscale(Scores on a scale)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Mean62.25 ± 18.03461.17 ± 17.691NA ± NA
Functional activity of the joint subscale
Functional activity of the joint subscale(Scores on a scale)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Mean61.46 ± 10.59965.57 ± 16.515NA ± NA
Life quality subscale
Life quality subscale(Scores on a scale)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Mean44.99 ± 17.00946.79 ± 17.507NA ± NA
Patient satisfaction assessment
Patient satisfaction assessment(Scores on a scale)Participants With Stage I-III Knee Osteoarthritis (KOA)Participants With Stage I-III Hip Osteoarthritis (HOA)Total
Mean3.2 ± 0.53.1 ± 0.423.1 ± 0.48
08

Study locations

2 sites
  • Sci-Res Institute of Rheumatology n.a. V.A. Nasonova of RAMS
    Moscow, 115522, Russian Federation
  • Many locations
    Multiple Locations, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2020, 27 months.

Results were first posted in Oct 2021, 1 year 6 months after primary completion.

Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's 27 months is below that.

Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Nov 6, 2017
StartActual
Nov 20, 2017
Primary completionActual
Mar 18, 2020
CompletionActual
Jul 13, 2020
Results first posted
Oct 14, 2021
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03330288
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 20, 2017
Primary completion
Mar 18, 2020
Completion
Jul 13, 2020
Results posted
Oct 14, 2021
Last update
Oct 14, 2021

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion